Genetics of malignant hyperthermia

TheScientificWorldJournal

Volumn 6, Issue , 2006, Pages 1722-1730

  Brandom, Barbara W ^a,b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c N Amer Malignant Hyperthermia Registry of MHAUS (Malignant Hyperthermia Assoc of the U States)   (United States)

Author keywords

Malignant hyperthermia; Ryanodine receptor type one

Indexed keywords

RYANODINE RECEPTOR 1; SELENOPROTEIN; SELENOPROTEIN N; UNCLASSIFIED DRUG;

CANCER SUSCEPTIBILITY; CENTRAL CORE DISEASE; CHROMOSOME 19Q; DIAGNOSTIC TEST; DUCHENNE MUSCULAR DYSTROPHY; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HYPOKALEMIC PERIODIC PARALYSIS; MALIGNANT HYPERTHERMIA; MYOPATHY; PHARMACOGENETICS; PHENOTYPE; POPULATION GENETICS; REVIEW;

ANIMALS; CALCIUM; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE (GENETICS); MALIGNANT HYPERTHERMIA; MUSCLE, SKELETAL; PHENOTYPE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SWINE;

EID: 33846004178     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2006.289     Document Type: Review

References (62)

1. MacLennan, D.H., Duff, C., Zorzato, F., Fujii, J., Phillips, M., Korneluk, R.G., Frodis, W., Britt, B.A., and Worton, R.G. (1990) Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 343, 559-561.
2. McCarthy, T.V., Healy, J.M.S., Heffron, J.A.J., Lelan, M., Deufel, T., Lehmann-Horn, F., Farrall, M., and Johnson, K. (1990) Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 343, 562-564.
3. Urwyler, A., Deufel, T., McCarthy, T., and West, S. (2001) Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br. J. Anaesth. 86, 283-287.
4. Girard, T., Treves, S., Voronkov, E., Siegemund, M., and Urwyler, A. (2004) Molecular genetic testing for malignant hyperthermia susceptibility. Anesthesiology 100, 1076-1080.
5. Girard, T., Jöhr, M., Schaefer, C., and Urwyler, A. (2006) Perinatal diagnosis of malignant hyperthermia susceptibility. Anesthesiology 104, 1353-1354.
6. Monnier, N., Krivosic-Horber, R., Payen, J.F., Kozak-Ribbens, G., Nivoche, Y., Adnet, P., Reyford, H., and Lunardi, J. (2002) Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 97, 1067-1074.
7. Phillips, M.S., Fujii, J., Khanna, V.K, De Leon, S., Yokobata K, de Jong, P.J., and MacLennan, D.H. (1996) The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. Genomics 34, 24-41.
8. Ruffert, H., Olthoff, D., Deutrich, C., Meinecke, C.D., and Froster, U.G. (2002) Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations. Acta Anaesthesiol. Scand. 46, 692-698.
9. Sei, S., Sambuughin, N.N., Davis, E.J., Sachs, D., Cuenca, P.B., Brandom, B.W., Tautz, T., Rosenberg, H., Nelson, T.E., and Muldoon, S.M. (2004) Malignant hyperthermia in North America: genetic screening of the three hot spots in the type 1 ryanodine receptor gene. Anesthesiology 101, 824-830.
10. Girard, T., Urwyler, A., Censier, K., Mueller C.R., Zorzato, F., and Treves, S. (2001) Genotype-phenotype comparison of the Swiss malignant hyperthermia population. Hum. Mutat. 18, 357-358.
11. Robinson, R.L., Anetseder, M.J., Brancadoro, V., van Broekhoven, C., Carsana, A., Censier, K., Fortunato, G., Girard, T., Heytens, L., Hopkins, P.M., Jurkat-Rott, K., Klinger, W., Kozak-Ribbens, G., Krivosic, R., Monnier, N., Nivoche, Y., Olthoff, D., Rueffert, H., Sorrentino, V., Tegazzin, V., and Mueller, C.R. (2003) Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur. J. Hum. Genet. 11, 342-348.
12. Robinson, R., Brooks, C., Brown, S.L., Ellis, F.R., Halsall, P.J., Quinnel, R.J., Shaw, M.A., and Hopkins, P.M. (2002) RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum. Mutat. 20, 88-97.
13. Monnier, N., Kozak-Ribbens, G., Krivosic-Horber, R., Nivoche, Y., Qi, D., Kraev, N., Loke, J., Sharma, P., Tegazzin, V., Figarella-Branger, D., Romero, N., Mezin, P., Bendahan, D., Payen, J.-F., Depret, T., MacLennan, D.H., and Lunardi, J. (2005) Correlations between genotype and pharmacological, histological, functional and clinical phenotypes in malignant hyperthermia susceptibility. Hum. Mutat. 26, 413-425.
14. Galli, L., Orrico, A., Lorenzini, S., Censini, S., Falciani, M., Covacci, A., Tegazzin, V., and Sorrentino, V. (2006) Frequency and localization of mutations in the 106 exons of the RYR1 gene I 50 individuals with malignant hyperthermia. Hum. Mutat. 27(8), 830.
15. Ibarra, M.C.A., Wu, S., Murayama, K., Minami, N., Ichihara, Y., Kikuchi, H., Noguchi, S., Hayashi, Y.K., Ochiai, R., and Nishino, I. (2006) Malignant hyperthermia in Japan mutation screening of the entire ryanodine receptor type one gene coding region by direct sequencing. Anesthesiology 101, 1146-1154.
16. Sambuughin, N., Holley, H., Muldoon, S., Brandom, B.W., de Bantel, A.M., Tobin, J.R., Nelson, T.E., and Goldfarb, L. (2005) Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia in the North American population. Anesthesiology 102, 515-521.
17. Larach, M.G., Localio, A.R., Allen, G.C., Denborough, M.A., Ellis, F.R., Gronert, G.A., Kaplan, R.F., Muldoon, S.M., Nelson, T.E., Ording, H., Rosenberg H., Waud, B.E., and Wedel, D.J. (1994) A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 80, 771-779.
18. Healy, J.M., Quane, K.A., Keating, K.E., Lehane, M., Heffron, J.J., and McCarthy, T.V. (1996) Diagnosis of malignant hyperthermia: a comparison of the in vitro contracture test with the molecular genetic diagnosis in a large pedigree. J. Med. Genet. 33, 18-24.
19. Brown, R.L., Pollock, A.N., Couchman, K.G., Hodges, M., Hutchinson, D.O., Waaka, R., Lynch, P., McCarthy, T.V., and Stowell, K.M. (2000) A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Hum. Mol. Genet. 12, 1515-1524.
20. Larach, M.G., Landis, J.R., Bunn, J.S., Diaz, M., The North American Malignant Hyperthermia Registry (1992) Prediction of malignant hyperthermia susceptibility on low-risk subjects. Anesthesiology 76, 16-27.
21. Girard, T., Levano, S., Singer, M., Matter, A., and Urwyler A. (2006) How Accurate Is Testing for Malignant Hyperthermia? American Society of Anesthesiologists Annual Meeting, October 14-18, Chicago. A1310.
22. Girard, T., Rueffert, H., and Po, A.L.W. (2006) Can We Improve on Phenotyping for Malignant Hyperthermia? American Society of Anesthesiologists Annual Meeting, October 14-18, Chicago. A1309.
23. MacLennan, D.H. (1995) Discordance between phenotype and genotype in malignant hyperthermia. Curr. Opin. Neurol. 8, 397-401.
24. Ball, S.P. and Johnson, K.J. (1993) The genetics of malignant hyperthermia. J. Med. Genet. 30, 89-93.
25. Levitt, R.C., Olckers, A., Meyers, S., Fletcher, J.E., Rosenberg, H., Isaacs, H., and Meyers, D.A. (1992) Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics 14, 562-566.
26. Iles, D.E., Lehman-Horn, F., Scherer, S.W., Tsui, L.-C., Olde Weghius, D., Suijkerbuijk, R.F., Heytens, L., Mikala, G., Schwartz, A., Ellis, F.R., Stewart, A.D., Deufel, T., and Wieringa, B. (1994) Localization of the gene encoding the α2/δ-subunits of the L-type voltage dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum. Mol. Genet. 3, 969-975.
27. Sudbrak, R., Procaccio, V., Klausnitzer, M., Curran, J., Monsieurs, K., Ellis, F.R., Heytens, L., Hartung, E.J., Kozak Ribbens, G., Heilinger, D., Weissenbach, J., Lehman-Horn, F., Mueller, C.R., Deufel, T., Stewart, A.D., and Lunardi, J. (1995) Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am. J. Hum. Genet. 56, 684-691.
28. 2+ channel (CACNL1A3) to chromosome 1q31-q32. Genomics 15, 107-112.
29. Robinson, R.L., Monnier , N., Wolz, W., Jung, M., Reis, A., Nuernberg, G., Curran, J.L., Monsieurs, K., Stieglitz, P., Heytens, L., Fricker, R., van Broeckhoven, C., Deufel, T., Hopkins, P.M., Lunardi, J., and Mueller, C.R. (1997) A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum. Mol. Genet. 6, 953-961.
30. Carsana, A., Forunato, G., De Sarno, C., Brancadoro, V., and Salvatore, F. (2003) Identification of new polymorphisms in the CACNA1S gene. Clin. Chem. Lab. 41, 20-22.
31. Caciotti, A., Morrone, A., Domenici, R., Donati, M.A., and Zammarchi, E. (2003) Severe prognosis in a large family with hypokalemic periodic paralysis. Muscle Nerve 27, 165-169.
32. Monnier, N., Procaccio, V., Stieglitz, P., and Lunardi, J. (1997) Malignant-hyperthermia susceptibility is associated with a mutation of the α-1 subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am. J. Hum. Genet. 60, 1316-1325.
33. Marchant, C.L., Ellis, F.R., Halsall, J., Hopkins, P.M., and Robinson, R. (2004) Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia. Muscle Nerve 30, 114-117.
34. Gregg, R.G., Powers, P.A., and Hogan, K. (1993) Assignment of the human gene for the β1-subunit of the voltage dependent calcium channel (CACNLAB1) to chromosome 17 using somatic cell hybrids and linkage mapping. Genomics 15, 185-187.
35. 2+ channel (CACNLG), cDNA sequence, gene structure, and chromosomal location. J. Biol. Chem. 268, 9269-9275.
36. Robinson, R., Hopkins, P., Carsana, A., Gilly, H., Halsall, J., Heytens, L., Islander, G., Jurkat-Rott, K., Clemens, M., and Shaw, M.A. (2003) Several interacting genes influence the malignant hyperthermia phenotype. Hum. Genet. 112, 217-218.
37. Olkers, A., Meyes, D.A., Meyes, S., Taylor, E.W., Fletcher, J.E., Rosenberg, H., and Isaacs, H. (1992) Adult muscle sodium channel α-subunit is a gene candidate for malignant hyperthermia susceptibility. Genomics 14, 562-566.
38. 1306 to alanine mutation in the adult muscle sodium channel α-subunit gene. Anesthesiology 82, 1097-1103.
39. Moslehi, R., Langlois, S., Yam, I., and Friedman, J.M. (1998) Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree. Am. J. Med. Genet. 76, 21-27.
40. Iles, D.E., Segers, B., Sengens, R.C.A., Monsiers, K., Heytens, L., Halsall, P.J., Hopkins, P.M., Ellis, F.R., Hall-Curran, J.L., Stewart, A.D., and Wieringa, B. (1993) Genetic mapping of the β11- and γ-subunits of the human skeletal muscle L-type voltage dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibility. Hum. Mol. Genet. 2, 863-868.
41. Sudbrak, R., Golla, A., Hogan, K., Powers, P., Gregg, R., Du Chesne, I., LehmannpHorn, F., and Deufel, T. (1993) Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on chromosome 17q and of the alpha 1, beta 1, and gamma subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect. Hum. Mol. Genet. 7, 857-862.
42. Gronert, G.A. (1995) Myotonias and masseter spasm:not malignant hyperthermia? Anesthesiology 83, 1382-1383.
43. Magee, K.R. and Shy, G.M. (1956) A new congenital non-progressive myopathy. Brain 79, 610-621.
44. Treves, S., Anderson, A.A., Ducreux, S., Divet, A., Bleunven, C., Grasso, C., Paesante, S., and Zorzato, F. (2005) Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders. Neuromuscul. Disord. 15, 577-587.
45. Quane, K.A., Keating, K.E., Healy, J.M., Manning, B.M., Krivosic-Horber, R., Krivosic, I., Monnier, N., Lunardi, J., and McCarthy, T.V. (1994) Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics 23, 236-239.
46. Ducreux, S., Zorzato, F., Ferreiro, A., Jungbluth, H., Muntoni, F., Monnier, N., Muller, C.R., and Treves, S. (2006) Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes. Biochem. J. 395, 259-266.
47. 2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and Central Core Disease mutations. J. Biol. Chem. 15, 15380-15389.
48. + handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys. J. 87, 3193-3204.
49. 2+ release channel function and severe central core disease. Proc. Natl. Acad. Sci. U. S. A. 96, 4164-4169.
50. Wu, S., Ibarra, M.C.A., Malicdan, M.C.V., Murayama, K., Ichihara, Y., Kikuchi, H., Nonaka, I., Noguchi, S., Hayashi, Y.K., and Nishino, I. (2006) Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 129, 1470-1480.
51. Ferreiro, A., Quijano-Roy, S., Pichereau, C., Moghadaszadeh, B., Goemans, N., Bonnemann, C., Jungbluth, H., Straub, V., Villanova, M., Leroy, J.P., Romero, N.B., Martin, J.J., Muntoni, F., Voit, T., Estournet, B., Richard, P., Fardeau, M., and Guicheney, P. (2002) Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am. J. Hum. Genet. 71, 739-749.
52. Jungbluth, H., Zhou, H., Hartley, L., Halliger-Keller, B., Messina, S., Longman, C., Brockington, M., Robb, S.A., Straub V., Voit, T., Swash, M., Ferreiro, A., Bydder, G., Sewry, C.A., Muller, C., and Muntoni, F. (2005) Minicore myopathy with opthalmoplegia caused by mutations in the ryanodine receptor type 1 gene. Neurology 65, 1930-1935.
53. Scacheri, P.C., Hoffman, E.P., Fratkin, J.D., Semino-Mora, C., Senchak, A., Davis, M.R., Laing, N.G., Vedanarayanon, V., and Subramony, S.H. (2000) A novel ryanodine receptor gene mutation causing both cores and rods in congenital myopathy. Neurology 55, 1689-1696.
54. Ferreiro, A., Monnier, N., Romero, N.B., Leroy, J.P., Bonnemann, C., Haenggeli, C.A., Straub, V., Voss, W.D., Nivoche, Y., Jungbluth, H., Lemainque, A., Voit, T., Lunardi, J., Fardeau, M., and Guicheney, P. (2002) A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the ryanodine receptor type 1 gene. Ann. Neurol. 51, 750-759.
55. Monnier, N., Romero, N.B., Lerale, J., Nivoche, Y., Qi, D., MacLennan, D.H., Fardeau, M., and Lunardi, J. (2000) An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. Hum. Mol. Genet. 9, 2599-2608.
56. Shukry, M., Guruli, Z.V., and Ramadhyani, U. (2006) Suspected malignant hyperthermia in a child with laminin alpha2 (merosin) deficiency in the absence of a triggering agent. Paediatr. Anaesth. 16, 462-465.
57. Larach, M.G., Rosenberg, H., Gronert, G.A., and Allen, G.C. (1997) Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin. Pediatr. (Phila.) 36, 9-16.
58. rd, Grix, A., Jr., Ellis, W.G., and Schwartz, M.Z. (1992) Absence of malignant hyperthermia contractures in Becker-Duchenne dystrophy at age 2. Muscle Nerve 15, 52-56.
59. Whitehead, N.P., Yeung, E.W., and Allen, D.G. (2006) Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin. Exp. Pharmacol. Physiol. 33, 657-662.
60. Woods, C.E., Novo, D., DiFranco, M., Capote, J., and Vergara, J.L. (2005) Propagation in the transverse tubular system and voltage dependence of calcium release in normal and mdx mouse muscle fibres. J. Physiol. 568, 867-880.
61. + binding proteins demonstrates decreased calsequestrin expression in dystrophic mouse skeletal muscle. Eur. J. Biochem. 271, 3943-3952.
62. Basset, O., Boittin, F.X., Dorchies, O.M., Chatton, J.Y., van Breemen, C., and Ruegg, U.T. (2004) Involvement of inositol 1,4,5-triphosphate in nicotinic calcium responses in dystrophic myotubes assessed by near-plasma membrane calcium measurement. J. Biol. Chem. 279, 47092-47100.